RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Janssen

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device.  Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

At Janssen, the pharmaceutical companies of Johnson & Johnson, our mission is to transform individual lives and change fundamentally the way diseases are managed, interpreted, and prevented. Bringing solutions and advancing science for the benefit of patients. They work with today’s informed and empowered patients to ensure our solutions are designed for and reach the people who need them. They work for change that will improve access to medicines: the best available treatment at an affordable price. That’s why they at Janssen strive to provide access to effective and affordable medicines and related health care services across the world.

<div>  <p>    At Janssen, the pharmaceutical companies of Johnson &amp; Johnson, our mission is to transform individual lives and change fundamentally the way diseases are managed, interpreted, and prevented. Bringing solutions and advancing science for the benefit of patients.  </p>  <p>    They work with today&rsquo;s informed and empowered patients to ensure our solutions are designed for and reach the people who need them. They work for change that will improve access to medicines: the best available treatment at an affordable price. That&rsquo;s why they at Janssen strive to provide access to effective and affordable medicines and related health care services across the world.  </p></div>

Janssen Pharmaceutica to lay off between 125 and 148 staff in Beerse

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>

 <p>Ailux Biologics, an AI-powered biologics discovery and engineering platform and a division of XtalPi, has entered a licensing agreement with global biotechnology company, Janssen Biotech. The deal licenses Janssen to use Ailux's proprietary biologics AI platform, XtalFold, which uses sequence data to model biomolecule interactions that are central to therapeutic substances like monoclonal antibodies. </p>
 <p>Through this agreement, Janssen will be able to expedite the discovery and engineering of new biotherapeutics by leveraging XtalFold. The AI platform has reportedly shown effectiveness in more than 30 programs and has demonstrated considerable promise in aspects such as antigen design and epitope identification among others.</p>
 
</div>

Janssen

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless